DBVT Articles, DBV Technologies S.A. - From 11/09/23

Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOP...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 (Article 223-16 o...

Montrouge, France, November 2, 2023 DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing inter...

Gainers Cellectis S.A. (NASDAQ: CLLS) shares surged 152% to $2.43 in pre-market trading. Cellectis reported strategic collaboration and investment ...

Montrouge, France, October 31, 2023 DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies a...

Montrouge, France, October 27, 2023 DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update DBV Technologies (Euronext...

Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euron...

                  Monthly information regarding the total number of voting rights and total number of shares of the Company as of Septem...

Montrouge, France, September 5, 2023 DBV Technologies to Participate in Upcoming Investor Conference DBV Technologies (OTC:DBVTF), a clinical-stag...

The Dow Jones closed higher by more than 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern arou...